Wave Life Sciences LTD Form 4 insider transactions

Wave Life Sciences Director Christian Henry reported acquiring restricted stock units and options, while also selling a portion of his ordinary shares under a pre-arranged trading plan.

Adrian Rawcliffe, a Director at Wave Life Sciences Ltd., was granted restricted share units and stock options as part of the company's 2025 Non-Employee Director Compensation Policy.

Wave Life Sciences Director Gregory L. Verdine received a grant of 12,700 restricted share units and options for 76,200 shares as part of the 2025 Non-Employee Director Compensation Policy.

Wave Life Sciences Director Ken Takanashi sold 4,872 ordinary shares at $8.75 each to cover tax obligations related to restricted share unit vesting.

Wave Life Sciences Director Tan Aik Na sold 1,127 ordinary shares at $8.75 each to cover tax obligations from restricted share unit vesting.

Gregory L. Verdine, a Director at Wave Life Sciences Ltd., sold 30,000 ordinary shares for approximately $6.95 per share on June 13, 2025, as part of a Rule 10b5-1 trading plan.

Christian Henry, a director at Wave Life Sciences, executed option exercises and share sales according to a pre-arranged Rule 10b5-1 trading plan.

Wave Life Sciences CEO Paul Bolno exercised share options and sold shares on March 7, 2025, according to a pre-arranged Rule 10b5-1 trading plan.

Gregory L. Verdine, a director at Wave Life Sciences, exercised stock options to acquire a total of 266,402 ordinary shares.

Chandra Vargeese, Chief Technology Officer of Wave Life Sciences, executed share options and disposed of ordinary shares on March 4, 2025.

Chief Financial Officer Kyle Moran of Wave Life Sciences Ltd. reports the acquisition of restricted share units, ordinary shares, and share options.

Wave Life Sciences CEO Paul Bolno reports the acquisition of 121,000 restricted share units and a grant of options to purchase 1,000,000 ordinary shares.

Chris Francis, SVP at Wave Life Sciences, reports the acquisition of 25,000 restricted share units and options to purchase 151,000 shares.

Chandra Vargeese, Chief Technology Officer of Wave Life Sciences, reports acquisition of restricted share units and share options.

Chandra Vargeese, Chief Technology Officer at Wave Life Sciences, exercised share options and acquired ordinary shares on January 23, 2025.

Wave Life Sciences CEO, Paul Bolno, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Wave Life Sciences CEO, Paul Bolno, sold 51,234 ordinary shares at a weighted average price of $14.32 per share under a pre-arranged 10b5-1 trading plan.

A Wave Life Sciences executive, Chris Francis, exercised stock options and sold the resulting shares under a pre-arranged 10b5-1 trading plan.

Chris Francis, SVP at Wave Life Sciences, executed option exercises and sales of ordinary shares under a pre-arranged Rule 10b5-1 trading plan.

Wave Life Sciences CEO Paul Bolno sold 90,474 ordinary shares at $15 per share on October 16, 2024, according to a Form 4 filing with the SEC.

Kyle Moran, CFO of Wave Life Sciences, exercised share options to acquire 25,000 ordinary shares at $2.48 each.

GSK plc reports acquiring additional shares of Wave Life Sciences Ltd., increasing its indirect ownership.

Kyle Moran, CFO of Wave Life Sciences Ltd., reports the sale of ordinary shares under a pre-arranged Rule 10b5-1 trading plan.

Wave Life Sciences CEO Paul Bolno sold 48,366 ordinary shares at an average price of $5.78 on August 21, 2024, under a pre-arranged Rule 10b5-1 trading plan.

RA Capital Management, along with related entities and individuals, reports changes in beneficial ownership of Wave Life Sciences Ltd. securities due to the grant of restricted share units and options to Dr. Peter Kolchinsky.

Director Adrian Rawcliffe reports acquisition of shares and options in Wave Life Sciences Ltd. as part of the 2024 Non-Employee Director Compensation Policy.

Director Aik Na Tan acquired shares and options in Wave Life Sciences Ltd. under the 2024 Non-Employee Director Compensation Policy.

Director Christian Henry reports acquisition of Wave Life Sciences shares and options as part of non-employee director compensation.

Director Mark Corrigan of Wave Life Sciences Ltd. reports the acquisition of stock options and restricted share units (RSUs) as part of the 2024 Non-Employee Director Compensation Policy.

Director Gregory L. Verdine reports acquisition of Wave Life Sciences shares and options as part of the 2024 Non-Employee Director Compensation Policy.